ABSTRACT Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three milli...

up to 30% of iranian adult multi-transfused thalassemic patients are infected with hepatitis c virus (hcv) which can intensify the progression of liver disease caused by iron overload in this group of patients. our aim was to assess the biochemical and virological response of interferon alfa (inf-α) and its safety in thalassemic patients with chronic hcv infection. this trial was a single cente...

this preliminary study was designed to evaluate the effects of heberon alfa for the treatment of chronic hepatitis b infected subjects in iran. a single center, open label, single treatment prospective study of interferon alfa (heberon alfa), 5 million units every other day for a period of 4 months, was performed between 1996 to 1998. a total number of 30 patients with histologically documented...

abstract background: combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis c today. the aim of this study was to evaluate the efficacy and safety of thrice-weekly heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis c. methods: a total of97 treatment-naive patients received heberon three millio...

This preliminary study was designed to evaluate the effects of Heberon Alfa for the treatment of chronic hepatitis B infected subjects in Iran. A single center, open label, single treatment prospective study of Interferon Alfa (Heberon Alfa), 5 million units every other day for a period of 4 months, was performed between 1996 to 1998. A total number of 30 patients with histologically docume...

Up to 30% of Iranian adult multi-transfused thalassemic patients are infected with hepatitis C virus (HCV) which can intensify the progression of liver disease caused by iron overload in this group of patients. Our aim was to assess the biochemical and virological response of interferon alfa (INF-α) and its safety in thalassemic patients with chronic HCV infection. This trial was a single c...